MedDataX Logo

The Effect of CYP3A Genetic Polymorphism on the Pharmacokinetics of Phosphodiesterase type5 Inhibitors in Male Subjects

NCT ID: NCT00767598

Last Updated: 2008-10-07

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

21 participants

Study Classification

INTERVENTIONAL

Study Start Date

2007-12-31

Study Completion Date

2008-07-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

In order to evaluate the effect of CYP3A5\*3 allele on the pharmacokinetics of sildenafil, udenafil, and vardenafil, the clinical trial using a single oral dose was conducted in Korean healthy male subjects whose genotype of CYP3A5 had been determined.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The aim of this study is to evaluate the different effect of the CYP3A5 genotype on the pharmacokinetics(PK) of sildenafil, udenafil, and vardenafil in healthy male subjects. Twenty one healthy male subjects with CYP3A5\*1/\*1, \*1/\*3, or \*3/\*3 were enrolled. An open-label 3-way crossover study was performed with a week washout. A single oral dose of PDE5I (100 mg sildenafil; 200 mg udenafil; 20 mg vardenafil) was administered, respectively. After a single oral dose of phosphodiesterase type 5 inhibitor (PDE5I), plasma levels of the parent and the major metabolite were measured up to 24 or 48 h.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Pharmacokinetics of Three PDE5Is Healthy Subjects Genetic Polymorphic CYP3A5

Keywords

Explore important study keywords that can help with search, categorization, and topic discovery.

CYP3A5 sildenafil udenafil vardenafil

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

A

Vardenafil

Group Type ACTIVE_COMPARATOR

phosphodiesterase type 5 inhibitor

Intervention Type DRUG

single oral administration of 20mg vardenafil

B

Sildenafil

Group Type ACTIVE_COMPARATOR

phosphodiesterase type 5 inhibitor

Intervention Type DRUG

single oral administration of 100mg sildenafil

C

Udenafil

Group Type ACTIVE_COMPARATOR

phosphodiesterase type 5 inhibitor

Intervention Type DRUG

single oral administration of 200mg udenafil

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

phosphodiesterase type 5 inhibitor

single oral administration of 20mg vardenafil

Intervention Type DRUG

phosphodiesterase type 5 inhibitor

single oral administration of 100mg sildenafil

Intervention Type DRUG

phosphodiesterase type 5 inhibitor

single oral administration of 200mg udenafil

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

vardenafil sildenafil udenafil

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male subject whose CYP3A5 genotype was determined

Exclusion Criteria

* Subject whose CYP3A5 genotype was not determined
Minimum Eligible Age

20 Years

Eligible Sex

MALE

Accepts Healthy Volunteers

Yes

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Inje University

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Inje University College of Medicine

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Jae-Gook Shin

Role: PRINCIPAL_INVESTIGATOR

Inje University

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

07-109

Identifier Type: -

Identifier Source: org_study_id